• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care
    Get the next $CRY alert in real time by email
    SC 13G/A 1 tv0648-cryolifeinc.htm SCHEDULE 13G/A cryolifeinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  CryoLife Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  228903100

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  228903100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    79,746

    7.  SOLE DISPOSITIVE POWER

    2,352,996

    8.  SHARED DISPOSITIVE POWER

    107,535

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,460,531

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.33%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    CryoLife Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1655 Roberts Boulevard, NW
    Kennesaw, Georgia 30144

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    228903100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    2,460,531

      (b) Percent of Class:

    6.33%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  79,746

    (iii)  sole power to dispose of or to direct the disposition of:  2,352,996

    (iv)  shared power to dispose or to direct the disposition of:  107,535

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $CRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRY

    DatePrice TargetRatingAnalyst
    1/7/2022$29.00 → $25.00Equal-Weight
    Morgan Stanley
    7/30/2021$31.00 → $32.00Equal-Weight
    Morgan Stanley
    7/30/2021$38.00 → $39.00Buy
    Needham
    7/15/2021$31.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously

    1/7/22 8:57:55 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously

    7/30/21 11:55:50 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Cryolife with a new price target

    Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously

    7/30/21 6:09:23 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/10/21 4:13:01 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/1/21 4:14:23 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)

    4 - CRYOLIFE INC (0000784199) (Issuer)

    11/30/21 4:40:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CryoLife Announces Corporate Rebranding and Changes Name to Artivion

    ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

    1/18/22 8:10:00 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,

    11/9/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Leadership Updates

    Live Leadership Updates

    View All

    Anthony Semedo Joins CryoLife Board of Directors

    ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali

    9/22/21 4:25:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    SEC Filings

    View All

    CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    1/20/22 4:36:16 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    8-A12B/A - CRYOLIFE INC (0000784199) (Filer)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CRYOLIFE INC (0000784199) (Filer)

    1/4/22 3:58:05 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Financials

    Live finance-specific insights

    View All

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

    ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes

    10/20/21 4:10:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Second Quarter 2021 Financial Results

    ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i

    7/29/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed

    SC 13G - CRYOLIFE INC (0000784199) (Subject)

    2/11/21 2:02:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care